Abstract P6-16-03: Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Trial ◽

Hormone Refractory

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30109-2 ◽

2017 ◽

Vol 18 (5) ◽

pp. 654-662 ◽

Cited By ~ 88

Author(s):

Hope S Rugo ◽

Lasika Seneviratne ◽

J Thaddeus Beck ◽

John A Glaspy ◽

Julio A Peguero ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Trial ◽

Hormone Receptor Positive

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2 ‐negative metastatic breast cancer

International Journal of Cancer ◽

10.1002/ijc.33613 ◽

2021 ◽

Author(s):

Hyehyun Jeong ◽

Jae Ho Jeong ◽

Jeong Eun Kim ◽

Jin‐Hee Ahn ◽

Kyung Hae Jung ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Protective Effects ◽

Phase 2 ◽

Hormone Receptor Positive ◽

Randomized Phase 2

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

Annals of Oncology ◽

10.1093/annonc/mdp328 ◽

2010 ◽

Vol 21 (3) ◽

pp. 493-497 ◽

Cited By ~ 9

Author(s):

W.W. Tan ◽

D.W. Hillman ◽

M. Salim ◽

D.W. Northfelt ◽

D.M. Anderson ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Metastatic Breast ◽

Phase 2 ◽

North Central ◽

Irinotecan Hydrochloride ◽

Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer

10.1158/1538-7445.sabcs20-pd3-06 ◽

2021 ◽

Author(s):

Shanu Modi ◽

Cristina Saura ◽

Toshinari Yamashita ◽

Yeon Hee Park ◽

Sung-Bae Kim ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

Annals of Oncology ◽

10.1093/annonc/mdx811 ◽

2018 ◽

Vol 29 (10) ◽

pp. 2150

Author(s):

W.W. Tan ◽

D.W. Hillman ◽

M. Salim ◽

D.W. Northfelt ◽

D.M. Anderson ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Metastatic Breast ◽

Phase 2 ◽

North Central ◽

Irinotecan Hydrochloride ◽

Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

10.1158/1538-7445.sabcs17-ot3-06-01 ◽

2018 ◽

Cited By ~ 1

Author(s):

PA Kaufman ◽

M Pipas ◽

GJ Finn ◽

SE Mathews ◽

H Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Systemic Therapy ◽

Metastatic Breast ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Hormone Receptor Positive ◽

Prior Systemic Therapy

Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial

10.1158/1538-7445.sabcs19-p1-19-08 ◽

2020 ◽

Author(s):

Hans Wildiers ◽

Valentina Boni ◽

Cristina Saura ◽

Mafalda Oliveira ◽

Komal Jhaveri ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Hormone Receptor Positive ◽

Basket Trial

Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1042 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1042-1042 ◽

Cited By ~ 3

Author(s):

Andrew David Seidman ◽

Lee Steven Schwartzberg ◽

Vinay K. Gudena ◽

Peter Rubin ◽

Stew Kroll ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Single Agent ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European Journal of Cancer ◽

10.1016/j.ejca.2014.10.008 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3077-3088 ◽

Cited By ~ 16

Author(s):

S.W. Lam ◽

S.M. de Groot ◽

A.H. Honkoop ◽

A. Jager ◽

A.J. ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Locally Recurrent ◽

First Line Treatment

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00106-6 ◽

2016 ◽

Vol 17 (6) ◽

pp. 811-821 ◽

Cited By ~ 140

Author(s):

Ian E Krop ◽

Ingrid A Mayer ◽

Vinod Ganju ◽

Maura Dickler ◽

Stephen Johnston ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Oestrogen Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽